The U.S. Food and Drug Administration (FDA) has issued a detailed Warning Letter (CBER 26-726330) to Scottsdale, Arizona-based R3 Medical Companies, its affiliated entities Bello Bio, LLC and Regen Suppliers, LLC, and CEO David L. Greene, M.D.
Following joint facility inspections, the FDA concluded that R3 Medical’s umbilical cord-derived products — including ReBellaWJ, ReBellaXO, ReBellaXOL, and ReBellaCB — are unapproved, unlicensed biological products distributed in violation of federal law. Furthermore, the agency documented significant Current Good Manufacturing Practice (CGMP) violations, deeming the products adulterated.
For medical director physicians, medspa owners, and integrative health providers offering regenerative treatments, this enforcement action serves as an urgent reminder: the FDA is aggressively scrutinizing the sale, promotion, and administration of unapproved stem cell and exosome therapies.
What Is the FDA’s Case Against R3 Medical Companies?
The warning letter issued by the Center for Biologics Evaluation and Research (CBER) details multiple overlapping regulatory violations under both the Federal Food, Drug, and Cosmetic Act (FD&C Act) and the Public Health Service Act (PHS Act).
1. Lack of FDA Approval or Biologics Licenses
To lawfully distribute biological products across state lines, a manufacturer must hold an approved Biologics License Application (BLA) demonstrating safety, purity, and potency. The FDA confirmed that R3 Medical Companies holds no approved BLA for ReBellaWJ, ReBellaXO, ReBellaXOL, or ReBellaCB, making their distribution illegal under Section 505(a) of the FD&C Act and Section 351(a)(1) of the PHS Act.
2. Failure to Qualify for 361 HCT/P Exemptions
Under 21 CFR Part 1271, human cells, tissues, or cellular/tissue-based products (HCT/Ps) can bypass premarket approval only if they meet strict criteria (often called “361 HCT/Ps”). The FDA determined R3’s line failed these requirements on multiple grounds:
- Non-Homologous Use: The products were advertised to treat conditions such as arthritis, neurological disease, autism, COPD, and erectile dysfunction. Treating systemic or degenerative diseases is not the natural, basic function of donor umbilical tissue or cord blood in the body.
- Systemic/Metabolic Action: ReBellaCB, for example, is dependent on the metabolic activity of living cells for its primary function, and it is not intended for autologous use or for allogeneic use in a first- or second-degree blood relative.
3. Severe CGMP Violations
Inspectors issued Form FDA-483 observations after documenting that Bello Bio and Regen Suppliers failed to meet basic sterility, process validation, and quality control requirements during manufacturing and private labeling. Because the products failed to conform to CGMP, the FDA classified them as adulterated under Section 501(a)(2)(B) of the FD&C Act.
Social Media and Digital Marketing Under the Regulatory Microscope
A notable aspect of the FDA’s warning letter is the extensive evidence gathered directly from R3 Medical’s marketing channels. Regulatory investigators analyzed:
- Corporate websites (r3stemcell.com, bello.bio, regensuppliers.com)
- YouTube videos (@R3StemCell)
- Instagram posts (@R3stemcellofficial) and Facebook posts (R3 Stem Cell, @r3stemcelltherapyofficial)
- TikTok videos (@r3stemcell)
In one specific YouTube video cited by the FDA, an employee was filmed holding vials of ReBellaCB and ReBellaXO in front of a professional athlete, claiming the vials contained 30 million stem cells each, along with anti-inflammatory exosomes to help recover from sports injuries.
The takeaway for practitioners: The FDA actively monitors digital media, promotional YouTube videos, and patient testimonials. Promoting unapproved biologics for therapeutic uses anywhere online establishes objective intent under federal law and triggers strict regulatory action.
Legal and Licensing Risks for Practices and Medical Directors
Wellness clinics, medical spas, and providers who purchase or administer unapproved exosome or umbilical cell products face compounded exposure:
- Medical Board Investigations: Purchasing unapproved active biological products from non-compliant suppliers and injecting them into patients breaches standard-of-care guidelines, placing professional medical and nursing licenses in immediate jeopardy.
- Loss of Malpractice Insurance Coverage: Most professional liability policies explicitly exclude coverage for claims, injuries, or legal actions arising from the use of unapproved, off-label biologicals or illegal substances.
- Civil and Product Liability Exposure: If a patient suffers an adverse event (e.g., severe infection, immune reaction, or lack of efficacy) from an adulterated or unapproved biological product, the administering clinic and supervising medical director carry immense financial and civil liability.
- Federal Regulatory Enforcement: Clinics sourcing unapproved biologics risk receiving FDA warning letters, facing inventory seizures, or becoming entangled in broader criminal misbranding investigations.
Actionable Compliance Steps for Medical Practices
To safeguard your practice, maintain license compliance, and protect patient health in light of heightened regulatory enforcement:
- Conduct an Immediate Inventory Audit: Immediately inspect all regenerative products, allografts, and exosome vials stored in your practice. Remove any biological products that lack FDA approval or a valid Investigational New Drug (IND) application.
- Verify Supplier Compliance: Ensure all tissue suppliers and compounding vendors strictly comply with FDA 351 biological licensure requirements. Do not rely solely on vendor marketing claims or internal “certificates of analysis.”
- Clean Up Marketing and Social Media: Audit your practice website, social media channels, and patient consent forms. Remove claims promising that exosome or stem cell therapies can treat specific medical conditions, chronic pain, or systemic diseases.
- Educate Clinical Staff and Patients: Ensure clinicians understand the regulatory boundary between legally compliant 361 tissue allografts and unapproved 351 biologics.
If your practice or medical spa has questions regarding regenerative medicine compliance, exosome regulation, or FDA rules, schedule a consultation with the Lengea Law team to evaluate your risk.